12.16 million yuan invested in R & D! Tenofovir dipivoxil hesco fumarate tablets approved

On April 10, hisic announced that its wholly-owned subsidiary Sichuan hisic Pharmaceutical Co., Ltd had recently received the approval document for drug registration of tenofovir dipivoxil fumarate tablets approved and issued by the State Drug Administration According to the announcement, on January 25, 2018, Sichuan hisic submitted an application for production application to Sichuan food and drug administration, which was accepted, officially approved for production recently, and obtained the approval document for drug registration Tenofovir fumarate dipivoxil tablets are the first nucleotide analogues used in the treatment of AIDS, which inhibit virus replication by blocking the reverse transcriptase involved in HIV replication Clinical research shows that it has strong antiviral effect and low incidence of drug resistance It can inhibit the replication of hepatitis B virus by interfering with the function of DNA polymerase of hepatitis B virus in human body, and has a broad application prospect in the treatment of chronic hepatitis B Upon inquiry, tenofovir dipivoxil fumarate tablets were initially developed by Gilead in the United States, and approved in 2001 to be used in combination with other antiretroviral drugs to treat HIV-1 infection in the United States; in 2008, it was approved in the United States to be used in the treatment of chronic hepatitis B (HBV), and the dosage forms were tablets and oral powder At present, tenofovir fumarate dipivoxil tablets have been listed in China In addition to the approved import of tenofovir fumarate dipivoxil tablets (trade name "wered") produced by Gilead pharmaceutical, Chengdu Beite Pharmaceutical Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., Anhui Baker biopharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd., Hangzhou SUPOR Nanyang Pharmaceutical Co., Ltd Nine domestic enterprises, including Industrial Co., Ltd., Shijiazhuang Longze Pharmaceutical Co., Ltd., Anhui Anke Hengyi Pharmaceutical Co., Ltd., GlaxoSmithKline (Tianjin) Co., Ltd and Sichuan HISCO Pharmaceutical Co., Ltd., have obtained the production approval documents for the drug According to IMS data, the global sales volume of tenofovir dipivoxil fumarate tablets in 2017 was US $1.52 billion; according to the data of minenet, the domestic sales volume of this product in 2017 was RMB 620 million The product of Chengdu Beite Pharmaceutical Co., Ltd was selected from the 4 + 7 city drug centralized procurement in 2018, with a median price of 17.72 yuan / box (specification: 300mg * 10 tablets / plate * 3 plates) Up to now, the company has invested about 12.16 million yuan in the research and development of tenofovir dipivoxil fumarate tablets.